These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 33305905)

  • 1. Suppression of tumor immune microenvironment via microRNA-1 after epidermal growth factor receptor-tyrosine kinase inhibitor resistance acquirement in lung adenocarcinoma.
    Kawana S; Saito R; Miki Y; Kimura Y; Abe J; Sato I; Endo M; Sugawara S; Sasano H
    Cancer Med; 2021 Jan; 10(2):718-727. PubMed ID: 33305905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Immune Microenvironment Comparation Study between EGFR Mutant and EGFR Wild Type Lung Adenocarcinoma Patients Based on TCGA Database].
    Zhu G; Li Y; Shi R; Xu S; Zhang Z; Cao P; Chen C; Liu H; Chen J
    Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):236-244. PubMed ID: 33910272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors.
    Yang CY; Liao WY; Ho CC; Chen KY; Tsai TH; Hsu CL; Su KY; Chang YL; Wu CT; Hsu CC; Liao BC; Hsu WH; Lee JH; Lin CC; Shih JY; Yang JC; Yu CJ
    Eur J Cancer; 2020 Jan; 124():110-122. PubMed ID: 31760310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma.
    Kang DH; Jung SS; Yeo MK; Lee DH; Yoo G; Cho SY; Oh IJ; Kim JO; Park HS; Chung C; Lee JE
    BMC Cancer; 2020 Jun; 20(1):571. PubMed ID: 32552717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR-200c-3p suppression is associated with development of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer via a mediating epithelial-to-mesenchymal transition (EMT) process.
    Wang HY; Liu YN; Wu SG; Hsu CL; Chang TH; Tsai MF; Lin YT; Shih JY
    Cancer Biomark; 2020; 28(3):351-363. PubMed ID: 32417760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction of a circRNA-miRNA-mRNA Regulated Pathway Involved in EGFR-TKI Lung Adenocarcinoma Resistance.
    Dai C; Liu B; Li S; Hong Y; Si J; Xiong Y; Wu N; Ma Y
    Technol Cancer Res Treat; 2021; 20():15330338211056809. PubMed ID: 34825849
    [No Abstract]   [Full Text] [Related]  

  • 7. Targeting YAP-p62 signaling axis suppresses the EGFR-TKI-resistant lung adenocarcinoma.
    Park HS; Lee DH; Kang DH; Yeo MK; Bae G; Lee D; Yoo G; Kim JO; Moon E; Huh YH; Lee SH; Jo EK; Cho SY; Lee JE; Chung C
    Cancer Med; 2021 Feb; 10(4):1405-1417. PubMed ID: 33486901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unique microRNAs in lung adenocarcinoma groups according to major TKI sensitive EGFR mutation status.
    Pak MG; Lee CH; Lee WJ; Shin DH; Roh MS
    Diagn Pathol; 2015 Jul; 10():99. PubMed ID: 26170125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposomal delivery of MicroRNA-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor-resistance in lung cancer cells.
    Rai K; Takigawa N; Ito S; Kashihara H; Ichihara E; Yasuda T; Shimizu K; Tanimoto M; Kiura K
    Mol Cancer Ther; 2011 Sep; 10(9):1720-7. PubMed ID: 21712475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-608 and miR-4513 significantly contribute to the prognosis of lung adenocarcinoma treated with EGFR-TKIs.
    Zhang N; Li Y; Zheng Y; Zhang L; Pan Y; Yu J; Yang M
    Lab Invest; 2019 Apr; 99(4):568-576. PubMed ID: 30552364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors.
    Balko JM; Potti A; Saunders C; Stromberg A; Haura EB; Black EP
    BMC Genomics; 2006 Nov; 7():289. PubMed ID: 17096850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NOTCH3 Overexpression and Posttranscriptional Regulation by miR-150 Were Associated With EGFR-TKI Resistance in Lung Adenocarcinoma.
    Zhang Y; Chen B; Wang Y; Zhao Q; Wu W; Zhang P; Miao L; Sun S
    Oncol Res; 2019 Jul; 27(7):751-761. PubMed ID: 30732676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shisa3 brakes resistance to EGFR-TKIs in lung adenocarcinoma by suppressing cancer stem cell properties.
    Si J; Ma Y; Bi JW; Xiong Y; Lv C; Li S; Wu N; Yang Y
    J Exp Clin Cancer Res; 2019 Dec; 38(1):481. PubMed ID: 31801598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A low microRNA-630 expression confers resistance to tyrosine kinase inhibitors in EGFR-mutated lung adenocarcinomas via miR-630/YAP1/ERK feedback loop.
    Wu DW; Wang YC; Wang L; Chen CY; Lee H
    Theranostics; 2018; 8(5):1256-1269. PubMed ID: 29507618
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical significance of serum EGFR gene mutation and serum tumor markers in predicting tyrosine kinase inhibitor efficacy in lung adenocarcinoma.
    Feng LX; Wang J; Yu Z; Song SA; Zhai WX; Dong SH; Yu HS; Zhang Y
    Clin Transl Oncol; 2019 Aug; 21(8):1005-1013. PubMed ID: 30637712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Significance of MMP-1 in EGFR-TKI-Resistant Lung Adenocarcinoma: Potential for Therapeutic Targeting.
    Saito R; Miki Y; Ishida N; Inoue C; Kobayashi M; Hata S; Yamada-Okabe H; Okada Y; Sasano H
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29463039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells.
    Kitamura K; Seike M; Okano T; Matsuda K; Miyanaga A; Mizutani H; Noro R; Minegishi Y; Kubota K; Gemma A
    Mol Cancer Ther; 2014 Feb; 13(2):444-53. PubMed ID: 24258346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
    Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
    Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
    Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
    Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative targeted proteomic analysis of potential markers of tyrosine kinase inhibitor (TKI) sensitivity in EGFR mutated lung adenocarcinoma.
    Awasthi S; Maity T; Oyler BL; Qi Y; Zhang X; Goodlett DR; Guha U
    J Proteomics; 2018 Oct; 189():48-59. PubMed ID: 29660496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.